InvestSMART

Avecho Biotechnology Limited (ASX: AVE) - Announcements

Current share price for AVE : $0.013 0.002 (13.33%)+

ASX company news and announcements for Avecho Biotechnology Limited (AVE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Avecho Biotechnology Limited (AVE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Avecho Biotechnology Limited (AVE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Avecho Biotechnology Limited (AVE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$50 Presentation to Ausbiotech Invest 2025 21 Oct 2025 8:29AM $0.006 $0.013 risen by 116.67%
$50 Update - Notification regarding unquoted securities - AVE 1 Oct 2025 8:52AM $0.006 $0.013 risen by 116.67%
$50 Appendix 4D and Half-year Financial Report 28 Aug 2025 3:16PM $0.006 $0.013 risen by 116.67%
$50 June 2025 Quarterly Activities Report & Appendix 4C 30 Jul 2025 8:44AM $0.005 $0.013 risen by 160%
$50 Phase III Insomnia Trial Recruitment Update 29 Jul 2025 9:08AM $0.005 $0.013 risen by 188.89%
$50 Change in Substantial Holding 25 Jun 2025 9:25AM $0.004 $0.013 risen by 225%
$50 Receipt of R&D Tax Incentive 28 May 2025 11:24AM $0.005 $0.013 risen by 160%
$50 Change of Director's Interest Notice x4 27 May 2025 3:02PM $0.005 $0.013 risen by 160%
$50 Notification regarding unquoted securities - AVE 27 May 2025 2:53PM $0.005 $0.013 risen by 160%
$50 2025 Annual General Meeting Results 27 May 2025 2:47PM $0.005 $0.013 risen by 160%
$50 Chair's Address and CEO Presentation 27 May 2025 12:28PM $0.005 $0.013 risen by 160%
$50 Phase III Trial Update - New Sites Commence Recruitment 20 May 2025 9:02AM $0.005 $0.013 risen by 188.89%
$50 March 2025 Quarterly Activities Report & Appendix 4C 30 Apr 2025 10:07AM $0.004 $0.013 risen by 225%
$50 Notice of Annual General Meeting/Proxy Form 24 Apr 2025 8:26AM $0.004 $0.013 risen by 225%
$50 Application for quotation of securities - AVE 16 Apr 2025 3:56PM $0.004 $0.013 risen by 225%
$50 Section 708A Cleansing Statement 16 Apr 2025 3:54PM $0.004 $0.013 risen by 225%
$50 Avecho receives initial US$3M upfront payment from Sandoz 28 Mar 2025 9:21AM $0.005 $0.013 risen by 160%
$50 Avecho to present at NWR Virtual Healthcare Conference 13 Mar 2025 8:43AM $0.006 $0.013 risen by 116.67%
$50 Appendix 4G and Corporate Governance Statement 7 Mar 2025 12:11PM $0.006 $0.013 risen by 116.67%
$50 Annual Report 31 December 2024 7 Mar 2025 12:07PM $0.006 $0.013 risen by 116.67%
$50 Licensing Webinar and Presentation 4 Mar 2025 10:23AM $0.007 $0.013 risen by 100%
$50 Avecho & Sandoz Sign Deal to Develop CBD for Insomnia in AUS 3 Mar 2025 9:46AM $0.007 $0.013 risen by 85.71%
$50 Trading Halt 28 Feb 2025 8:53AM $0.007 $0.013 risen by 85.71%
$50 Appendix 4E - Preliminary Final Report 28 Feb 2025 8:29AM $0.007 $0.013 risen by 85.71%
$50 Response to ASX Price Query 14 Feb 2025 1:11PM $0.007 $0.013 risen by 100%

51 - 75 of 321 results

Page 3 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.